[Click eStock] "Celltrion Hits Bottom and Enters Rebound Phase... Target Price Raised to 250,000 Won"

On January 2, NH Investment & Securities raised its target price for Celltrion to 250,000 won, stating that the stock has reached the bottom of its valuation range.

Han Seungyeon, a researcher at NH Investment & Securities, said, "We expect Celltrion to break out of its long-term trading range in 2026."

Researcher Han noted, "Despite the rise in the KOSPI, Celltrion's stock price has remained trapped in a box range," but added, "However, it has finally reached a historical valuation low." Han also stated, "Thanks to strong fourth-quarter results and expectations for the January JPM Healthcare conference, the stock has entered a phase of sustained rebound," and assessed that "it is an optimal time for new purchases."

Accordingly, Han explained, "We raised the multiple to reflect 2026 EBITDA, adjusted target multiples, and the recent strong performance of competitor biosimilar companies," and set the new target price at 250,000 won, a 9% increase from the previous target.

This year, Han estimates Celltrion's sales at 5.1 trillion won and operating profit at 1.7 trillion won. These figures represent increases of 24% and 48%, respectively, compared to the previous year.